ClinicalTrials.gg
Active, not recruitingNCT05439655Updated Oct 15, 2026Results posted

Acute Recording of Stereotyped High-Frequency Oscillations

An interventional study of Brain Interchange System in Epilepsy, sponsored by Mayo Clinic. Active, not recruiting at 2 sites in United States. Open to participants aged 3 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2021, registered Jun 2022).
Updated Oct 15, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
3 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Epilepsy by Mayo Clinic — 5 open to participants now, 8 under way, none of them phase 3. Epilepsy · Mayo Clinic.

Enrollment
5th of 18
17 · median 8
Started
2021
with 1 other
No phase
12 of 21
4 open now
Registered
15th of 21
by date

Among the 21 studies in Epilepsy by Mayo Clinic, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 15th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

5 of the 21 studies in Epilepsy by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 3 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Epilepsy by Mayo Clinic, or all of them as a file.
02

Study summary

Overall, this study will investigate the functional utility of stereotyped HFOs by capturing them with a new implantable system (Brain Interchange - BIC of CorTec), which can sample neural data at higher rates >=1kHz and deliver targeted electrical stimulation to achieve seizure control. In contrast to current closed-loop systems (RNS), which wait for the seizure to start before delivering stimulation, the BIC system will monitor the spatial topography and rate of stereotyped HFOs and deliver targeted stimulation to these HFO generating areas to prevent seizures from occurring. If the outcomes of our research in an acute setting become successful, the investigators will execute a clinical trial and run the developed methods with the implantable BIC system in a chronic ambulatory setting.

Read the detailed description

High-frequency oscillations (HFOs) of intracranial EEG (iEEG) have the potential to identify the surgical resection area/seizure onset zone (SOZ) in patients with drug-resistant epilepsy. However, multiple reports indicate that HFOs can be generated not only by epileptic cerebral tissue but also by non-epileptic sites often including eloquent regions such as motor, visual, and language cortices. In this project, the initial evidence of a recurrent waveform pattern is presented that may be sufficient to distinguish pathological HFOs from physiological ones. Specifically, the investigators show that the SOZ repeatedly generates sets of stereotypical HFOs with similar waveform morphology whereas the events recorded from out of SOZ were irregular. This morphological pattern served as a robust neurobiomarker to isolate SOZ from other brain areas in multiple patients consistently. While these promising preliminary results are in place, the functional utility of stereotyped HFOs in a closed-loop seizure control system remains unknown. As of today, not much is known whether the stereotyped HFOs generated by the SOZ can be detected with an implantable system. If this can be achieved, then HFOs can be strategically translated as a neurobiomarker into closed-loop seizure control applications. The investigators hypothesize that pathologic stereotyped HFOs can be captured with the implantable Brain Interchange (BIC) system of CorTec and spatial topography of these events can be utilized by the implantable system to deliver targeted electrical stimulation to achieve seizure control. Using an acute setup within the epilepsy monitoring unit (EMU), this project will investigate the feasibility of capturing stereotyped HFO events using the new BIC system and compare the detection results to those obtained with the commercially available amplifier (Aim-1). If the first phase (Aim-1) of the study becomes successful, later in the second phase (Aim-2), once again in the EMU, the investigators will deliver targeted electrical stimulation to those brain sites associated with stereotyped HFOs using the BIC.

During the entire study, the BIC system will not be implanted but used externally to assess the neural data through externalized electrodes and then deliver closed-loop stimulation. If the outcomes of the research in an acute setting become successful, the investigators will execute a clinical trial and run our methods with the implanted BIC system in a chronic ambulatory setting.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Neuromodulation
  • HFO
  • Epilepsy
  • Machine Learning
  • Closed-Loop
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
3 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with medically epilepsy, who have been deemed appropriate candidates for intracranial EEG monitoring
  • Adult men and women (18≤ age ≤64 years)
  • children (3≤ age \<18 years)
  • includes women and minorities

Exclusion criteria

Exclusion Criteria:

  • Subjects will be excluded if their condition makes them unable to continue with recordings.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Epilepsy

    patients with drug resistant epilepsy undergoing a surgical evaluation in the epilepsy monitoring unit

    Device: Brain Interchange System

Interventions

  • DeviceBrain Interchange System

    The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.

06

What researchers measure

Primary outcomes

  1. Packet Loss Rate

    Assessed by the percentage of transmitted data packets (a small unit of information that a device sends across a network) that were not successfully received and recorded by the BIC system in the epilepsy monitoring unit.

    Time frame: Over 24 hours

  2. Percentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC Recordings

    The outcome was calculated as the proportion of HFO events detected by the clinical amplifier that were also retained in the BIC recording during the 24-hour EMU recording period. The reported value represents a percentage calculated from the total number of retained HFO events divided by the total number of HFO events detected by the clinical amplifier. Because this outcome measure is an event-based proportion calculated from counts of detected HFOs rather than a participant-level variable measured for each participant, a measure type of Number was used rather than a measure of central tendency.

    Time frame: Over 24 hours

  3. Accuracy of BIC-Derived High Frequency Oscillations for Localization of the Seizure Onset Zone

    Evaluated the ability of BIC-derived HFOs to localize the seizure onset zone during a 24-hour EMU recording.

    Time frame: Over 24 hours

07

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneEpilepsy
Started15
Completed13
Not completed2

Outcome measures

PrimaryPacket Loss Rate

Assessed by the percentage of transmitted data packets (a small unit of information that a device sends across a network) that were not successfully received and recorded by the BIC system in the epilepsy monitoring unit.

Time frame:
Over 24 hours
Reported as:
Mean · percentage of data packets
Packet Loss Rate
percentage of data packetsEpilepsy
Packet Loss Rate0.55 ± 0.33
PrimaryPercentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC Recordings

The outcome was calculated as the proportion of HFO events detected by the clinical amplifier that were also retained in the BIC recording during the 24-hour EMU recording period. The reported value represents a percentage calculated from the total number of retained HFO events divided by the total number of HFO events detected by the clinical amplifier. Because this outcome measure is an event-based proportion calculated from counts of detected HFOs rather than a participant-level variable measured for each participant, a measure type of Number was used rather than a measure of central tendency.

Time frame:
Over 24 hours
Reported as:
Number · percentage of HFOs
Percentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC Recordings
percentage of HFOsEpilepsy
Percentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC Recordings82
PrimaryAccuracy of BIC-Derived High Frequency Oscillations for Localization of the Seizure Onset Zone

Evaluated the ability of BIC-derived HFOs to localize the seizure onset zone during a 24-hour EMU recording.

Time frame:
Over 24 hours
Reported as:
Number · percentage
Accuracy of BIC-Derived High Frequency Oscillations for Localization of the Seizure Onset Zone
percentageEpilepsy
Sensitivity84
Specificity90

Adverse events

Collected over Adverse events were collected for during the time of study device use, approximately 24 hours.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epilepsy0/15 (0%)0/15 (0%)0/15 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Epilepsy
Mean31.87 ± 18.89
Sex: Female, Male
Sex: Female, Male(Participants)Epilepsy
Female7
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Epilepsy
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Epilepsy
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Epilepsy
United States15
08

Study locations

2 sites
09

References and documents

Publications

  • Ayyoubi AH, Fazli Besheli B, Quach MM, Gavvala JR, Goldman AM, Swamy CP, Bartoli E, Curry DJ, Sheth SA, Francis DJ, Ince NF. Benchmarking signal quality and spatiotemporal distribution of interictal spikes in prolonged human iEEG recordings using CorTec wireless brain interchange. Sci Rep. 2024 Feb 8;14(1):2652. doi: 10.1038/s41598-024-52487-5. PubMed 38332136 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Intracranial EEG + ECoG recorded from patients with epilepsy will be shared. The electrical signs of neural activity will be collected in the EMU for 24hrs. One stream of data will be digitized at 1kHz with 16bit resolution with the BIC system and the other stream with least a 2 kHz sampling frequency to capture HFOs reaching up to 500Hz. All collected data will be de-identified prior to data exchange. Patient data will be provided in a coded format that protects patient identities but will contain diagnosis (signs/symptoms), interventions including technical observations, diagnostic tests/results, and patient outcomes. Information about the recording device including device serial numbers, device model numbers, date of the event, and country/state of the event will be annotated with the data.

Time frame: Every 6 months

Access criteria: Data Archive for the BRAIN Initiative (DABI) - invasive human neurophysiology (including EEG, ECoG, LFP, single unit)

Data sharing details ↗ · www.dandiarchive.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2025, 47 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's 47 months is close to that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2022
First posted
Jun 30, 2022
StartActual
Sep 1, 2021
Primary completionActual
Aug 11, 2025
CompletionEst.
Oct 31, 2026was Aug 2026
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Study completion
Aug 11, 2026→Oct 31, 2026
Oct 15, 2026
Enrollment
12→17
Oct 15, 2026
Eligibility
Maximum age 70 Years→64 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAdult men and women (18≤ age <70≤64 years)
Oct 15, 2026
Primary outcomes
3 added, 2 removed
What changed in the outcomes
  • AddedPacket Loss RateTime frame: Over 24 hours
  • AddedPercentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC RecordingsTime frame: Over 24 hours
  • AddedAccuracy of BIC-Derived High Frequency Oscillations for Localization of the Seizure Onset ZoneTime frame: Over 24 hours
  • RemovedRobustness in Data TransmissionTime frame: Over 24 hours within the first year of project
  • RemovedFeasibility of Detection of Stereotyped HFOsTime frame: Within the first 3 years of the project
Oct 15, 2026
Documents
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Study completion Aug 11, 2026→Oct 31, 2026
    Enrollment 12→17
    Eligibility Maximum age 70 Years→64 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAdult men and women (18≤ age <70≤64 years)
    Primary outcomes 3 added, 2 removed
    What changed in the outcomes
    • AddedPacket Loss RateTime frame: Over 24 hours
    • AddedPercentage of Clinical Amplifier-Detected High Frequency Oscillations (HFOs) Retained in BIC RecordingsTime frame: Over 24 hours
    • AddedAccuracy of BIC-Derived High Frequency Oscillations for Localization of the Seizure Onset ZoneTime frame: Over 24 hours
    • RemovedRobustness in Data TransmissionTime frame: Over 24 hours within the first year of project
    • RemovedFeasibility of Detection of Stereotyped HFOsTime frame: Within the first 3 years of the project
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05439655
Lead sponsor
Mayo Clinic
Responsible party
Nuri F. Ince (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jun 30, 2022
Start date
Sep 1, 2021
Primary completion
Aug 11, 2025
Completion
Oct 31, 2026 (estimated)
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Nuri F Ince, Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion